The first patient has been enrolled in a Phase 3 clinical trial of nebulized Tyvaso (treprostinil) inhalation solution for treating progressive pulmonary fibrosis (PPF), according to United Therapeutics, the therapy’s developer. Called TETON PPF (NCT05943535), the study will evaluate how safe Tyvaso is versus a placebo…
News
The pharmaceutical company Humanetics will use a federal grant to fund a series of studies aimed at advancing the development of BIO 300 for idiopathic pulmonary fibrosis (IPF) — for one, testing the treatment candidate for its effectiveness in easing lung scarring, or fibrosis. BIO 300 is thought to…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF). Breakthrough therapy designation is intended to expedite the development and review of medicines for serious or life-threatening diseases. The decision is based on preliminary…
Use of cancer chemotherapy agents or rituximab to treat autoimmune diseases was associated with an increased risk of pulmonary fibrosis (PF) in people hospitalized with COVID-19, according to a large-scale U.S. study. Exposure to these medications, along with anti-inflammatory corticosteroids and amiodarone, used to treat certain heart rhythm disorders,…
LYT-100, PureTech Health’s oral treatment candidate for idiopathic pulmonary fibrosis (IPF), was well tolerated among healthy older adults at doses leading to much higher amounts of active medication in the body than the approved dose of Esbriet (pirfenidone). That’s according to new data from Phase 1 clinical…
Proteins called histones can trigger lung fibrosis (scarring) by prompting platelets, cell fragments involved in blood clotting, to release a signaling molecule called transforming growth factor beta 1 (TGFB1), a new study found. TGFB1, in turn, blocks the production of interleukin-27 (IL-27), a signaling molecule that normally helps to limit…
Treatment with AP01, Avalyn Pharma‘s experimental inhaled formulation of pirfenidone, appears to be slightly more effective for idiopathic pulmonary fibrosis (IPF) than the oral version, which is sold as Esbriet, and results in fewer side effects. AP01’s efficacy and safety profiles with progressive forms of pulmonary…
The experimental oral therapy BMS-986278, taken at 60 mg twice daily for 26 weeks, resulted in a 69% reduction in the rate of lung function decline in adults with progressive pulmonary fibrosis taking part in a Phase 2 trial. These findings are consistent with previously reported data from…
A Phase 2a clinical trial to evaluate the safety and efficacy of ENV-101 (taladegib), Endeavor BioMedicines’ oral treatment for idiopathic pulmonary fibrosis (IPF), has completed patient enrollment. Top-line data from the study (NCT04968574), which enrolled 41 adults with mild-to-moderate IPF, ages 40 and older, at sites in…
The first patients have been dosed in the Phase 2 REVERTIPF trial testing Tvardi Therapeutics’ investigational therapy TTI-101 in people with idiopathic pulmonary fibrosis (IPF). TTI-101 is an oral small molecule inhibitor of STAT3, a protein implicated in pulmonary fibrosis (PF), as well as certain types of cancer. The…
